Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Hanover – page 8

648 clinical trials in Hanover, Germany across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Hanover at a glance
648
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

648 trials in Hanover

Open in trial search

Obstructive sleep apnoea syndrome

Recruiting

Study of Maridebart Cafraglutide for Adults with Obstructive Sleep Apnea and Overweight or Obesity Who Use Positive Airway Pressure Therapy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Proctitis

Recruiting

Study of budesonide suppositories to treat acute radiation proctitis in men with prostate cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:Dr. Falk Pharma GmbH

Metabolic dysfunction-associated liver disease

Recruiting

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:LY3437943 sodium
  • Sponsor:Eli Lilly & Co.

Breast cancer metastatic

Recruiting

Phase 1b-2 Study of Elacestrant and Abemaciclib in Patients with Brain Metastases from ER-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Stemline Therapeutics Inc.

Pulmonary arterial hypertension

Recruiting

A Study of ROC-101 Hydrochloride for Patients with Pulmonary Arterial Hypertension and Pulmonary Hypertension Associated with Interstitial Lung Disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ROC-101 hydrochloride
  • Sponsor:Allrock Bio Inc.

Hepatitis D

Recruiting

A study comparing brelovitug to bulevirtide for treating chronic hepatitis delta infection in patients currently receiving bulevirtide

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BJT-778
  • Sponsor:Mirum Pharmaceuticals Inc.

Type IIa hyperlipidaemia

Recruiting

A Study of Enlicitide for Safety and Effectiveness in Children and Adolescents with Heterozygous Familial Hypercholesterolemia

Investigational
Countries:GermanyGermany
  • Participants:0–17 years
  • Sponsor:Merck Sharp & Dohme LLC

Acute myeloid leukaemia

Recruiting

A study of bleximenib combined with intensive chemotherapy for adults with newly diagnosed acute myeloid leukemia with specific genetic changes.

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bleximenib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Hepatitis D+1

Recruiting

Study of GS-4321 for Healthy People and Patients With Chronic Hepatitis Delta Virus Infection

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:GS-4321
  • Sponsor:Gilead Sciences Inc.

Parkinson's disease

Recruiting

A study comparing prasinezumab with placebo for people with early-stage Parkinson's disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Prasinezumab
  • Sponsor:F. Hoffmann-La Roche AG

Osteoarthritis

Recruiting

A Study of Orforglipron for Knee Pain Relief in Adults with Obesity or Overweight and Knee Osteoarthritis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Eli Lilly & Co.

Neovascular age-related macular degeneration

Recruiting

Study of Surabgene Lomparvovec Compared to Ranibizumab for Adults with Wet Age-Related Macular Degeneration

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ranibizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Hanover

What the registry says about research in the country

01 Respiratory Diseases

Clinical trials focusing on respiratory infections and conditions, including studies of vaccines against RSV and human metapneumovirus in older adults. Research also includes treatment evaluation for chronic obstructive pulmonary disease.

  • RSV vaccine development
  • COPD treatment innovations
  • Viral respiratory infections

Multiple studies are evaluating novel therapeutic approaches for both acute and chronic respiratory conditions.

02 Oncology Research

Innovative trials in cancer treatment, including studies for bladder cancer, multiple myeloma, and advanced breast cancer. Research focuses on combination therapies and novel treatment approaches.

  • Immunotherapy combinations
  • Blood cancer treatments
  • Targeted therapies

Studies emphasize personalized treatment approaches and immune system-based therapies.

03 Neurological Conditions

Research focusing on neurodegenerative diseases, particularly Alzheimer's Disease and Amyotrophic Lateral Sclerosis. Studies evaluate new diagnostic tools and therapeutic interventions.

  • Early-stage dementia treatment
  • ALS therapeutic development
  • Brain clearance mechanisms

Trials aim to address both symptomatic treatment and disease progression.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.